Skip to main content
Articles & Publications , Thierry Van Nieuwenhove

Translational Pharmaceutics® Platform Remains a Primary Goal for Quotient Sciences

Thierry Van Nieuwenhove

In this article by 247 BioPharma, Thierry Van Nieuwenhove, the CEO of Quotient Sciences discusses the primary company goals and what steps the Quotient Sciences is taking to meet evolving regulatory requirements.

In addition, Thierry talks about the importance of partnerships and collaborations for the Quotient Sciences growth strategy and what key innovations, or new products will company be showcasing at CPHI Milan this year.

Continue reading the full article or watching the video on 247Bio Pharma.

Latest news from Quotient Sciences

More News
News & Announcements, Articles & Publications, Thierry Van Nieuwenhove Thierry Van Nieuwenhove on the Future of CDMO Partnerships By: Thierry Van Nieuwenhove
Read More
News & Announcements, Translational Pharmaceutics®, Articles & Publications BioPharm International interviews Helen Baker about how Quotient Sciences is optimizing drug development
Read More
Get in touch
Humanity can't afford to wait, so neither can we.